Fujifilm to Operate its Updated Enterprise Imaging Platform on U.S. DoD Networks

FUJIFILM Healthcare Americas Corporation’s Synapse 7x—its next-generation enterprise imaging platform—has been granted a Risk Management Framework (RMF) and Authority to Operate (ATO) on U.S. Department of Defense (DoD) networks, the company announced. 
 
The ATO was awarded to Fujifilm for its upgraded platform after nearly five years of operating on the firm’s earlier platform, Synapse 5.

“The U.S. government standards for security are extremely high, demonstrating Fujifilm has exceeded the strictest expectations for securing our technology,” said Bill Lacy, senior vice president, medical informatics, FUJIFILM Healthcare Americas Corporation. “We are proud to have earned the ATO for our Synapse 7x Enterprise Imaging technology, which is poised to improve data access throughout the military health system.”
 
Synapse 7x unites data and imaging from radiology, mammography, cardiology, 3D, and other enterprise imaging solutions on server-side, rendering technology that is both hardware independent as well as cloud deployable. With Synapse 7x, organizations within the DoD network can access a PACS platform that extends across the enterprise, an expansion from a radiology specific PACS platforms. 
 
The DoD’s RMF provides a process that integrates security and risk management activities into the system development life cycle. The risk-based approach to security control selection and specification considers effectiveness, efficiency, and constraints due to applicable laws, directives, executive orders, policies, standards, and regulations.
 
FUJIFILM Healthcare Americas Corporation is a healthcare company boasting a range of technology and expertise in disease detection, diagnosis, and treatment. Fujifilm’s medical imaging portfolio includes solutions for digital radiography, mammography, CT, MRI, ultrasound, gastroenterology, pulmonology, endosurgery, and minimally invasive surgery. The Synapse Enterprise Imaging portfolio provides healthcare professionals with the cross-departmental imaging and data access needed to deliver a complete patient record. Fujifilm’s AI initiative, REiLI, combines Fujifilm’s rich image-processing heritage with cutting-edge innovations to inspire clinical confidence and combat burnout. The In-Vitro Diagnostic portfolio provides the gold standard of molecular based immunoassay technology for liver surveillance, cutting edge clinical diagnostic chemicals for leading laboratories and diagnostic chemicals for OEM white labelling products. The company is headquartered in Lexington, Mass. 
 
FUJIFILM Holdings Corporation, Tokyo, leverages its depth of knowledge and proprietary core technologies to produce products and services in healthcare, materials, business innovation, and imaging. Fujifilm is committed to responsible environmental stewardship and good corporate citizenship. For the year ended March 31, 2023, the company generated approximately 2.9 trillion yen ($21 billion at an exchange rate of 134 yen/dollar) in revenue.